Please login to the form below

trial failures

This page shows the latest trial failures news and features for those working in and with pharma, biotech and healthcare.

Reviews start for Pfizer’s wildcard lung cancer drug dacomitinib

Regulatory reviews have started for Pfizer’s non-small cell lung cancer drug dacomitinib on both sides of the Atlantic, four years after a pair of trial failures left its future ... Dacomitinib missed its objectives in two phase III trials reported in

Latest news

Pharma sales help Bayer escape the worst from a bumpy 2017

easy”. For its pharmaceuticals business the ‘downs’included several late-stage trial failures towards the end of the year. ... Among them were a 7, 000 patient study of Xarelto in secondary stroke, a combination trial of Eylea and a drug-device
Merck BACE inhibitor adds to litany of Alzheimer's trial failures

Merck BACE inhibitor adds to litany of Alzheimer's trial failures. Interim data shows “ virtually no chance” of clinical success for verubecestat. ... The EPOCH trial enrolled patients with established mild-to-moderate Alzheimer symptoms and was due
Choose or lose

In essence, it involves sifting through thousands of 'industry episodes' such as launches, trial results, acquisitions and failures. ... The latest trial results from Amgen point out how its model is trying to create clear space from statins.
Tau protein drug fails late-stage trial

Tau protein drug fails late-stage trial. Alzheimer’ s disease therapy only showed benefit in patients with no existing treatments. ... Much of the pharma industry's efforts in Alzheimer's have been directed at the amyloid plaques seen in the brains of
Double trial disappointment for Roche

Roche's pipeline took a double hit today with disappointing trial results in both Alzheimer's disease and oncology. ... in the area considering multiple trial failures for investigational treatments in a later stage of the neurological condition.

More from news
Approximately 5 fully matching, plus 27 partially matching documents found.

Latest Intelligence

Interview: AstraZeneca's Susan Galbraith

major trial failures meaning the company was looking unlikely to fill the void created by patent expiries of key drugs.
An eye towards the biobetter in South Korea

Smaller entities such as Isu Abxis are listed companies whose stock prices and financial stability are especially vulnerable to trial failures. “ ... Some companies already have their biobetter pipelines in clinical trial stage.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

AstraZeneca hires Roche’s Pascal Soriot as CEO

a series of clinical trial failures leading to the departure of AZ's previous CEO Brennan in April, 2012.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Alzheimer’s disease: reviewing the immediate treatment horizon

However, the learnings from these ‘ failures’ have paved the way for the robust pipeline of treatments that could potentially be coming to market in the next five years. ... A recent article by BLH Consultant David Cooney explored the bleak

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager: Competitive salary commensurate with experience

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Scientific Communications Director - Oncology – In House Pharma ...: Neg

Senior Project Manager - Medical Writing: Great salary and bebefits

Home based, Senior Medical Writer, Medical Communications: Excellent package

Client Services Director – Healthcare Advertising - London: Neg

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Home based, Principal Medical Writer, Medical Communications: Excellent package

Account Director, Medical Communications: C£50 – 65, 000 benefits and bonus

Home based, Chief Medical Writer, Medical Communications: Excellent package

Delivery Manager/ Head of Delivery – Executive Search: Neg

Home based, Editorial Team Leader, Medical Communications: Excellent package

Business Unit Head, Medical Communications, London: Excellent package

Healthcare PR Director: £100, 000 – £120, 000 benefits

Account Manager: £40, 000 - £45, 000 benefits

Editorial Director – Medical Education (MedComms): Neg

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Client Services Director - Med Comms: Great salary and bebefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Strategic Planner, Healthcare Advertising: £47, 000 – £53, 000

Account Director, Consumer Healthcare PR, Global PR agency: £50, 000 – £58, 000

Subscribe to our email news alerts

PMHub

Add my company

Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Developing advocacy in the pharmaceutical industry.: The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?: Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?: The modern approach to B2B sales is data-driven, and enabled by digital tools....